SPX3,768.96-56.37 -1.47%
DIA305.51-5.34 -1.72%
IXIC11,095.75-32.09 -0.29%

GSK Says Vaccine Candidate Against Respiratory Syncytial Virus Showed 'Clinically Meaningful' Efficacy in Phase 3 Trial

MT Newswires · 06/10/2022 03:30

Please log in to view news